Puerta, JMJiménez Velasco, AGarcía, MJMolina, JRRuiz, CFerrer, CDurán, MSSimón, IClavero, EAvellaneda, MCRosell, ABallesteros, IRamírez, SPortero, MARamírez, MJFernández, MJiménez, MFe, RMulero, NLópez, P2016-10-032016-10-032016-06Puerta JM, Jiménez Velasco A, García MJ, Molina JR, Ruiz C, Ferrer C, et al.Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC). Haematologica. 2016; 101(s1).PB18200390-6078http://hdl.handle.net/10668/2445Even though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinib on ENESTnd and Dasision clinical trials.enDasatinibHumanosMesilato de imatinibLeucemia mielogenosa crónica BCR-ABL positivaPirimidinasSistema de registrosAndalucíaMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Thiazoles::DasatinibMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::Imatinib MesylateMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::PyrimidinesMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registriesconference presentationopen access1592-8721